The impact of HIV on tuberculosis control - Towards concerted action

Leprosy Review

Volumn 73, Issue 4, 2002, Pages 376-385

  Godfrey Faussett, Peter ^a   Ayles, Helen ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

AFRICA; ARTICLE; CASE FINDING; DISEASE TRANSMISSION; EPIDEMIC; HEALTH SERVICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MYCOBACTERIUM TUBERCULOSIS; PATIENT COUNSELING; SEROPREVALENCE; SHORT COURSE THERAPY; SPUTUM EXAMINATION; TUBERCULOSIS; TUBERCULOSIS CONTROL;

AFRICA SOUTH OF THE SAHARA; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; PREVALENCE; PREVENTIVE HEALTH SERVICES; TUBERCULOSIS, PULMONARY;

EID: 0036952448     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle, 1991; 72: 1-6.
2. An expanded DOTS framework for effective tuberculosis control. Int J Tuberc Lung Dis, 2002; 6: 378-388.
3. WHO. Global Tuberculosis Control. WHO Report 2001. World Health Organization, Geneva, 2001.
4. UNAIDS. Report on the Global HIV/AIDS epidemic. UNAIDS, Geneva, 2002.
5. Cantwell MF, Binkin NJ. Impact of HIV on tuberculosis in sub-Saharan Africa: a regional perspective. Int J Tuberc Lung Dis, 1997; 1: 205-214.
6. Wilkinson D, Davies GR. The increasing burden of tuberculosis in rural South Africa-impact of the HIV epidemic. S Afr Med J, 1997; 87: 447-450.
7. Elliott AM, Hawken MP. The changing pattern of clinical tuberculosis in the AIDS era: the role for preventive therapy. Bailliere's Clin Infect Dis, 1997; 4: 63-76.
8. Farmer P. Social scientists and the new tuberculosis. Soc Sci Med, 1997; 44: 347-358.
9. Ngamvithayapong J, Yanai H, Winkvist A et al. Feasibility of home-based and health centre-based DOT: perspectives of TB care providers and clients in an HIV-endemic area of Thailand. Int J Tuberc Lung Dis, 2001; 5: 741-745.
10. Godfrey-Faussett P, Kaunda H, Kamanga J. Why do patients with a cough delay seeking care at Lusaka Urban Health Centres? A Health Systems Research approach. Int J Tuberc Lung Dis, 2002; 6: in press.
11. Kamanga J, Kaunda H, Kambashi A. How likely are TB patients to be acurately diagnosed in urban health centres in Lusaka, Zambia? XIIth International Conference on AIDS 1998, Geneva.
12. De Cock KM, Chaisson RE. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis, 1999; 3: 457-465.
13. Geiter L (ed.) Ending neglect: the elimination of tuberculosis in the United States. National Academy Press, Washington, D.C., 2000.
14. Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis, 1979; 119: 827-830.
15. Mwinga A, Hosp M, Godfrey-Faussett P et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS, 1998; 12: 2447-2457.
16. Pape JW, Jean SS, Ho JL et al. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection [see comments]. Lancet, 1993; 342: 268-272.
17. Whalen CC, Johnson JL, Okwera A et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration [see comments]. N Engl J Med, 1997; 337: 801-808.
18. Gordin F, Chaisson RE, Matts JP et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beim Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA, 2000; 283: 1445-1450.
19. Halsey NA, Coberly JS, Desormeaux J et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet, 1998; 351: 786-792.
20. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep, 2000; 49: 1-51.
21. Preventive therapy against tuberculosis in people living with HIV. Wkly Epidemiol Rec, 1999; 74: 385-398.
22. Quigley MA, Mwinga A, Hosp M et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS, 2001; 15: 215-222.
23. Johnson IL, Okwera A, Hom DL et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS, 2001; 15: 2137-2147.
24. Sonnenberg P, Murray J, Glynn JR et al. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet, 2001; 358: 1687-1693.
25. Baggaley R, Kelly M, Weinreich S et al. HIV counselling and testing in Zambia: the Kara Counselling experience. SAfAIDS News, 1998; 6: 2-8.
26. Efficacy of voluntary HIV-1 counselling and testing in individuals and couples in Kenya, Tanzania, and Trinidad: a randomised trial. The Voluntary HIV-1 Counseling and Testing Efficacy Study Group. Lancet, 2000; 356: 103-112.
27. Elzinga G, Nunn P. TB and HIV: joint problems, joint solutions? Bull World Health Org, 2002; 80: 469-470.
28. Nunn P, Harries A, Godfrey-Faussett P et al. The research agenda for improving health policy, systems performance, and service delivery for tuberculosis control: a WHO perspective. Bull World Health Org, 2002; 80:471-476.
29. Wiktor SZ, Sassan-Morokro M, Grant AD et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet, 1999; 353: 1469-1475.
30. Boix V, Merino E, Portilla J. Highly active antiretroviral therapy for patients with tuberculosis: the solution or the problem? AIDS, 2002; 16: 1436-1437.
31. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet, 2002; 359: 2059-2064.
32. Weidle PJ, Malamba S, Mwebaze R et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet, 2002; 360: 34-40.
33. Macdonald N, Evans B. Increased high risk sexual behaviour in homosexual men. There is no evidence for a decreased incidence of HIV infection. BMJ, 2000; 321: 1531-1532.
34. Taylor S, Ferguson NM, Cane PA et al. Dynamics of seminal plasma HIV-1 decline after antiretroviral treatment. AIDS, 2001; 15: 424-426.
35. Anderson RM, May RM, Boily MC et al. The spread of HIV-1 in Africa: sexual contact patterns and the predicted demographic impact of AIDS. Nature, 1991; 352: 581-589.
36. Maher D, Hausler HP, Raviglione MC et al. Tuberculosis care in community care organizations in sub-Saharan Africa: practice and potential. Int J Tuberc Lung Dis, 1997; 1: 276-283.
37. Grosskurth H, Mosha F, Todd J et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet, 1995; 346: 530-536.
38. Osborne CM, van Praag E, Jackson H. Models of care for patients with HIV/AIDS. AIDS, 1997; 11: S135-141.
39. Strategic Framework to decrease the burden of TB/HIV. WHO Stop TB Department and Department of HIV/AIDS, Geneva, 2002.
40. Mills A, Amoako KY, Kato T. Round table. The work of the Commission on Macroeconomics and Health. Bull World Health Org, 2002; 80: 164-166.
41. Kondro W. Low profile for health at Kananaskis G8 summit. Lancet, 2002; 360: 61.